Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment.
The local immune response to influenza virus infection was characterized by determining cytokine and chemokine levels in serial nasal lavage fluid samples from 15 volunteers experimentally infected with influenza A/Texas/36/91 (H1N1). The study was part of a randomized double-blind placebo-controlled trial to determine the prophylactic effect of intravenous zanamivir (600 mg 2x/day for 5 days), a highly selective inhibitor of influenza A and B virus neuraminidases, on the clinical symptoms of influenza infection. Nasal lavage fluid levels of interleukin (IL)-6, tumor necrosis factor-alpha, interferon-gamma, IL-10, monocyte chemotactic protein-1, and macrophage inflammatory protein-1alpha and -1beta increased in response to influenza virus infection and correlated statistically with the magnitude and time course of the symptoms. Treatment with zanamivir prevented the infection and abrogated the local cytokine and chemokine responses. These results reveal a complex interplay of cytokines and chemokines in the development of symptoms and resolution of influenza.
Fritz
R S
RS
Science Applications International Corporation Frederick, Frederick Cancer Research and Development Center, Frederick, Maryland, USA.
Hayden
F G
FG
Calfee
D P
DP
Cass
L M
LM
Peng
A W
AW
Alvord
W G
WG
Strober
W
W
Straus
S E
SE
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001831:Body Temperature; D018925:Chemokines / Q000032:analysis / Q000096:biosynthesis*; D016207:Cytokines / Q000032:analysis / Q000096:biosynthesis*; D004311:Double-Blind Method; D006146:Guanidines; D006801:Humans; D009980:Influenza A virus; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control; D007275:Injections, Intravenous; D008297:Male; D017817:Nasal Lavage Fluid / Q000276:immunology*; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D010919:Placebos; D011714:Pyrans; D012794:Sialic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D053243:Zanamivir
D000998:Antiviral Agents; D018925:Chemokines; D016207:Cytokines; D006146:Guanidines; D010919:Placebos; D011714:Pyrans; D012794:Sialic Acids; D009439:Neuraminidase; D053243:Zanamivir